A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs CD40L GVAX (Primary) ; Aldesleukin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Prednisone; Vincristine
- Indications Mantle-cell lymphoma
- Focus Pharmacodynamics
- 15 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
- 09 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 16 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.